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SUMMARY. Achalasia is a relatively rare primary motor esophageal disorder, characterized by absence of relax-
ations of the lower esophageal sphincter and of peristalsis along the esophageal body. As a result, patients typically
present with dysphagia, regurgitation and occasionally chest pain, pulmonary complication and malnutrition. New
diagnostic methodologies and therapeutic techniques have been recently added to the armamentarium for treating
achalasia. With the aim to offer clinicians and patients an up-to-date framework for making informed decisions on
the management of this disease, the International Society for Diseases of the Esophagus Guidelines proposed and
endorsed the Esophageal Achalasia Guidelines (I-GOAL). The guidelines were prepared according the Appraisal of
Guidelines for Research and Evaluation (AGREE-REX) tool, accredited for guideline production by NICE UK. A
systematic literature search was performed and the quality of evidence and the strength of recommendations were
graded according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Given
the relative rarity of this disease and the paucity of high-level evidence in the literature, this process was integrated
with a three-step process of anonymous voting on each statement (DELPHI). Only statements with an approval
rate >80% were accepted in the guidelines. Fifty-one experts from 11 countries and 3 representatives from patient
support associations participated to the preparations of the guidelines. These guidelines deal specifically with the fol-
lowing achalasia issues: Diagnostic workup, Definition of the disease, Severity of presentation, Medical treatment,
Botulinum Toxin injection, Pneumatic dilatation, POEM, Other endoscopic treatments, Laparoscopic myotomy,
Definition of recurrence, Follow up and risk of cancer, Management of end stage achalasia, Treatment options for
failure, Achalasia in children, Achalasia secondary to Chagas’ disease.
KEYWORDS: esophageal achalasia, Chagas disease.
SUMMARY TABLE OF STATEMENTS AND
RECOMMENDATIONS
Topic and number Statement
Consensus
agreement score Recommendation
Diagnosis of
achalasia
1 High-resolution manometry is the test of
choice for the diagnosis of achalasia
(compared to conventional manometry)
94.2% We recommend the use of HRM for the
diagnosis of esophageal achalasia.
Conditional recommendation; GRADE low.
2 The Chicago Classification is a useful tool
to define the clinically relevant
phenotypes of achalasia.
90.4% We recommend classification of achalasia
according to the Chicago Classification.
Good practice recommendation
3 The timed barium esophagram offers an
objective evaluation of the diseases and of
the outcome after treatment (compared to
traditional barium esophagram).
90%. We recommend the adoption of TBS in the
diagnostic pathway of achalasia and to
evaluate the outcome of treatment.
Conditional recommendation; GRADE low.
4 Endoscopy should be performed in
patients with suspected achalasia to
exclude malignancy of the
esophagogastric junction.
98.1% We recommend performing UGI endoscopy
in adult with the suspected diagnosis of
achalasia to exclude neoplastic
pseudoachalasia. Good practice
recommendation.
5 The Eckardt score is a simple tool to
measure symptom severity in achalasia
patients, but it should be integrated with
objective measures such esophagogram
and manometry.
86.5% We recommend the use of the Eckardt score
as part of the initial and follow-up assessment
in patients with achalasia. Good practice
recommendation.
Treatment of
achalasia
Medical treatment
with nitrates, calcium
blockers, or
phosphodiesterase
6 There is no convincing evidence that
medical treatment with nitrates is effective
for symptomatic relief in adults with
achalasia.
86.5% We recommend against the use of nitrates,
calcium blockers, or phosphodiesterase
treatment for achalasia. GRADE: low.
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Topic and number Statement
Consensus
agreement score Recommendation
7 There is no convincing evidence that
medical treatment with calcium blockers is
effective for (short term) symptomatic
relief in adults with achalasia.
88.2%
8 In adults with achalasia, there is no evidence
that medical treatment with phospho-
diesterase inhibitors is effective for
symptomatic relief.
84.3%
Botulinum toxin
injection (BTI)
9 BTI has limited application in young
patients (aged less than 50 years).
92.3% We recommend against the use of BTI in patients
under 50 years of age, for control of symptoms.
GRADE: very low: We recommend against BTI
as an effective therapy (control of symptoms) for
achalasia in patients fit for surgery (LHM) or
pneumatic dilatation GRADE: moderate.
10 BTI should be reserved for patients who
are unfit for surgery or as a bridge to more
effective therapies, such as surgery or
endoscopic dilation
94.3%
11 Repeat treatments with Botox are safe, but
less effective than initial treatment
82.4% Recommendation: Botox injection can be safely
repeated, but the clinician and the patients should
be aware that their efficacy is lower than in initial
treatment. Conditional recommendation.
GRADE: low.
12 There is no evidence for supporting the
injection of Botox in the lower esophageal
body (in addition to injection in the LES)
in type III achalasia patients.
92.1% We recommend against BTI in the esophageal
body, even in the presence of type III achalasia.
GRADE: very low.
13 There is no evidence that patients
undergoing repeat BTI of the LES should
be treated with increasing dosage of BT.
96.1% We recommend against the use of increasing BT
dosage at retreatment. GRADE: very low.
Pneumatic dilatation
14 In patients with achalasia, graded PD is an
effective treatment in terms of
improvement of symptoms and swallowing
function.
90.4% We recommend graded pneumatic dilatations as
an effective treatment (control of symptoms
including dysphagia) for esophageal achalasia.
Strong recommendation GRADE: moderate.
Patients wishing longer term remission may opt
for surgical treatment.
15 In patients with achalasia who have
received PD, the best post procedural test
to assess if a perforation occurred is a
Gastrografin (iodine contrast) swallow.
80.8% We recommend that after PD patients are
observed for 4 hours. Water-soluble iodine
contrast (Gastrografin) esophagogram (or CT
scan with oral contrast) should be performed if
any symptoms, even if moderate, suggest that
perforation is present after dilatation. We
recommend against the routine use of contrast
esophagram or computed tomography shortly
after PD. Conditional recommendation.
GRADE: low.
16 There is only limited evidence that
pneumatic dilatation may be used as
first-line therapy in megaesophagus
(diameter >6 cm & sigmoid shaped).
82.4% We make no recommendation about pneumatic
dilatation as first-line therapy in megaesophagus
GRADE: very low.
17 There is no evidence that patients
undergoing graded dilation should be
treated with proton pump inhibitors as
maintenance therapy after the procedure,
unless symptomatic or positive at 24-hour
pH-monitoring.
94.3% We recommend against the prophylactic use of
PPI after PD, unless GERD symptoms are
present or objective evidence of reflux is
demonstrated. Conditional recommendation
GRADE: very low.
Peroral endoscopic
myotomy (POEM)
18 Treatment of achalasia patients with
POEM, results in similar outcomes on
swallowing functions compared with
alternative treatment (Heller myotomy or
PD), at least at medium term follow-up
(2–4 years).
88.4% We recommend POEM as an effective therapy
(control of symptoms) for achalasia both in
short- and medium-term follow-up with results
comparable to Heller myotomy for symptom
improvement. Conditional recommendation.
GRADE: very low. We recommend POEM as an
effective therapy (control of symptoms) for
achalasia both in short- and medium-term
follow-up with results comparable to pneumatic
dilations for control of symptoms. Conditional
recommendation. GRADE: low.
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Continued
Topic and number Statement Consensus
agreement score
Recommendation
19 Treatment of achalasia with POEM is
associated with a higher incidence of
GERD compared to alternative therapies
(Heller myotomy with fundoplication or
PD).
96.2% We recommend that pretreatment information on
the risk of GERD should be provided to the
patient and follow-up acid suppression therapy
considered after POEM. Good practice
recommendation. Patients who seek a
nonsurgical treatment (PD) or surgical treatment
with a lower incidence of postprocedure GERD
(Heller myotomy) should be counseled that these
options exist.
20 There is no evidence that previous
treatment of patients with achalasia with
PD or Botox reduces the technical
feasibility of POEM and results in poorer
outcomes.
86.6% We recommend POEM as feasible and effective
for symptom relief in patients previously treated
with previous endoscopic therapies. Conditional
recommendation; GRADE: very low.
21 POEM is an appropriate treatment for
symptom persistence/recurrence after
laparoscopic myotomy.
88.2% We recommend the use of POEM for symptom
relief, as an option for treating recurrences after
LHM. Conditional recommendation. GRADE:
low.
22 Attaining proficiency with the POEM
procedure involves a stepwise approach to
education and a defined learning curve
for both medical and surgical
endoscopists.
90.2% We recommend that appropriate training with in
vivo/in vitro animal model and adequate
proctorship should be considered before starting
a clinical program of POEM. Good practice
recommendation.
Alternative
treatments:
retrievable stents and
intrasphincteric
injection with
ethanolamine oleate
or polidocanol
23 There is little evidence to support that
modified retrievable stent placement at the
LES is an effective treatment for patients
with achalasia.
98% We recommend against temporary (retrievable or
absorbable) stents and intrasphincteric injection
with ethanolamine oleate for achalasia.
Conditional recommendation. GRADE: low.
24 There is no or little evidence to support the
use of endoscopic sclerotherapy with
ethanolamine oleate or polidocanol as an
effective first treatment for patients with
achalasia.
96% We recommend against temporary (retrievable or
absorbable) stents and intrasphincteric injection
with ethanolamine oleate or polidocanol for
achalasia. Conditional recommendation.
GRADE: low.
Laparoscopic Heller
myotomy
25 The best outcomes for LHM are achieved
in (Chicago) type I & type II achalasia
patients.
90.4% We recommend laparoscopic Heller myotomy for
control of symptoms in Chicago type I and type
II achalasia. Strong recommendation. GRADE:
moderate.
26 Laparoscopic Heller myotomy should
include a myotomy 6 cm into the
esophagus and 2 to 3 cm into the stomach
as measured from the GEJ, for effective
symptom control in achalasia
patients.
94.2% We recommend that Laparoscopic Heller
cardiomyotomy should be extended at least (6 cm
proximal to the GEJ and at least 2 cm distal to
the GEJ. Conditional recommendation.
GRADE: low.
27 Partial fundoplication should be added to
laparoscopic myotomy in patients with
achalasia to reduce the risk of subsequent
gastroesophageal reflux.
94.2% We recommend that a partial (posterior or
anterior fundoplication) but not a complete 360◦
wrap should be added to reduce the long-term
risk (5 years) of developing gastroesophageal
reflux and dysphagia after myotomy. Strong
recommendation. GRADE: moderate.
28 Laparoscopic Heller myotomy with a
partial fundoplication is as effective at
improving swallowing function as
laparoscopic Heller myotomy alone.
82.7% We recommend a partial fundoplication should
be used when performing Heller myotomy to
prevent subsequent development of gastro-
esophageal reflux without compromising the
adequate control of dysphagia. We recommend
against LHM alone due to the risk development
of gastro-esophageal reflux. Strong
recommendation. GRADE: High.
29 LHM (or other therapies as POEM or PD)
should be considered as the first-line
treatment option in achalasia patients with
sigmoid esophagus (compared to
esophagectomy).
86.5% We recommend standard endoscopic or surgical
therapies in surgically naı¨ve achalasia patients
with sigmoid-shaped esophagus, leaving
esophagectomy as secondary option
in case of failure of first line therapy. Conditional
recommendation. GRADE: very low.
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Continued
Topic and number Statement Consensus
agreement score
Recommendation
Recurrence of
achalasia after
treatment
30 Symptom improvement is the most
relevant clinical parameter for defining the
success of surgical or endoscopic treatment
for achalasia.
90.4% We recommend assessment of symptomatic
improvement as the best measure of success after
treatment of achalasia. Good practice
recommendation.
31 In adults with achalasia, there is no
universal definition of failure after any
treatment.
88.4% Recommendation: see next statement.
32 Recurrent symptoms after achalasia
treatment should routinely undergo repeat
objective testing.
100% We recommend objective testing in patients who
suffer recurrent symptoms after treatment of
achalasia including UGI endoscopy, barium
swallow, manometry, and 24-hour pH
monitoring. Good practice recommendation.
33 The timed barium swallow objectively
demonstrates the failure of achalasia
treatment in patients with
persistent/recurrent symptoms.
82.7% We recommend TBS as a reliable method to
assess recurrence of achalasia. Conditional
recommendation. GRADE: Low.
Risk of cancer
34 Achalasia patients carry a moderately
increased risk of development of squamous
esophageal cancer 10 years or more from
the primary treatment of achalasia.
86.5% We recommend that achalasia patients should be
informed that a moderately increased risk of
esophageal cancer is present in male after at least
10 years from the initial treatment of the disease.
Good practice recommendation. We make no
recommendation about routine endoscopy or
endoscopy intervals after any treatment.
Management of
treatment failures
35 Patients with achalasia who do not respond
to initial treatment with graded PD, should
be referred for Heller myotomy or POEM.
94.2% We recommend that in patients who are fit for
surgery and have symptomatic recurrences after
several pneumatic dilations, Heller myotomy, or
POEM should be considered. Conditional
recommendation. GRADE: of evidence
low.
36 Laparoscopic esophageal myotomy is a
safe, feasible and effective treatment after
failed Botox injection for achalasia.
96.2% We recommend LHM as an effective therapy for
symptom recurrence after primary treatment with
BTI. Conditional recommendation. GRADE:
very low.
37 PD, compared with repeat myotomy or
POEM, is the first option for treatment
after failed Heller myotomy for achalasia.
80.8% We recommend pneumatic dilation as a safe and
effective treatment of symptom recurrences after
LHM. Conditional recommendation. GRADE:
Low.
38 There is insufficient evidence that
laparoscopic myotomy or redo POEM
offer better results than PDs after failed
POEM.
82.4% We make no recommendation about laparoscopic
myotomy or redo POEM offering better
symptomatic relief than pneumatic dilations after
failed POEM. Further research is recommended
to provide high-quality data and guide clinical
decisions.
Diagnosis and
treatment of end
stage achalasia
39 Barium swallow esophagram, compared
with manometry, is the best diagnostic
method for defining end stage achalasia
(i.e. that which requires esophagectomy).
94.1% We recommend the use of barium swallow as the
most accurate investigation to properly define
end-stage achalasia. Good practice
recommendation.
40 Esophagectomy is indicated in patients
with persistent or recurrent achalasia after
failure of previous less invasive treatments
(PD, POEM, LHM) and radiologic
progression of the disease.
80.8% We recommend esophagectomy in patients with
end-stage achalasia who have failed other less
invasive interventions. Conditional
recommendation. GRADE: Low.
Achalasia in children
41 Children with suspected achalasia should
follow the same diagnostic pathway as that
of adult patients.
96% We recommend that children with a provisional
diagnosis of achalasia should undergo the same
work-up as in the adult population. Good
practice recommendation.
42 Surgical or endoscopic myotomy
(compared to dilation) is the preferred
treatment for pediatric patients with
idiopathic achalasia (IA), especially for
those aged 5 years or more.
80% We recommend myotomy (either through a
laparoscopic or flexible endoscopy approach as
the preferred treatment in children). Conditional
recommendation. Grade: very low.
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Continued
Topic and number Statement Consensus
agreement score
Recommendation
43 BTI is not an appropriate first-line therapy
in very young children with achalasia.
81.6% We recommend against BTI as a first-line therapy
in very young children with achalasia (with
exceptions for those children who are medically
frail and at high-risk for surgical intervention).
Conditional recommendation. Grade: very low.
44 The long-term outcome of achalasia
treatment in children should be assessed by
symptoms, function, physical growth, and
general development.
94.4% We recommend that the long-term outcome of
achalasia treatment in children should be closely
monitored by symptoms, swallowing function,
physical growth, and general development. Good
practice recommendation.
Diagnosis and
management of
achalasia secondary
to Chagas disease
45 There are minor differences between the
clinical presentation of IA and achalasia
secondary to Chagas disease.
86.2% We recommend that diagnostic techniques used
for IA should also be used for CDE, due to the
similarities in manometric and clinical features.
Conditional recommendation. GRADE: low.
46 There are no differences in the treatment of
idiopathic achalasia and achalasia specific
to Chagas disease.
90% We recommend that all treatments for IA may be
used for CDE for symptom relief. Conditional
recommendation. GRADE: low.
INTRODUCTION
Achalasia is a relatively rare esophageal motor dis-
order characterized by the absence of swallow-induced
relaxation of the lower esophageal sphincter (LES)
and by absence of peristalsis along the esophageal
body. Consequently, the transit of the food into
the stomach is impaired and the patient typically
experiences dysphagia. Other symptoms reported are
regurgitation of saliva or undigested food, respiratory
symptoms (nocturnal cough, recurrent aspiration,
and pneumonia), heartburn, and chest pain.1 The
most common form of achalasia is idiopathic and is
mostly observed sporadically. In idiopathic achalasia
(IA), the disease occurs secondary to the destruc-
tion of the myenteric plexus that coordinates both
peristaltic contraction and LES relaxations.2-4 A
similar clinical picture can be present in patients with
local or distant cancer (pseudoachalasia)5,6 or in
patients with Chagas’ disease,7 both characterized
by the destruction of the myenteric plexus either by
infiltrating tumors or by circulating autoantibodies
or by Trypanosoma cruzi infection.
The incidence of achalasia is similar in most coun-
tries, with no differences in gender and race, although
its incidence increases with age. It has been consis-
tently estimated that the incidence varies between 0.7
to 1.6 per 100,000 inhabitants/year.8-11 The preva-
lence of achalasia was currently estimated to be 10
per 100,000 inhabitants. Newer studies in the era
of high-resolution esophageal manometry (HRM)
suggest that these numbers are low, and that the
actual incidence is 2 to 3/100,000 with a much higher
prevalence.12-14
Achalasia is a chronic disease and all the current
treatment options can only palliate symptoms, but not
cure the disease. As a result, many achalasia patients
undergo multiple treatments throughout their life-
time.1
The diagnosis of achalasia is based on tests which
include: esophageal manometry that measures the
pressure generated in the LES and in the esophageal
body; barium esophagram and upper gastrointestinal
endoscopy, mainly to rule out the presence of cancer
(pseudoachalasia) and possible complications of the
disease (candidiasis).
Achalasia treatments are aimed at reducing the
pressure of the LES either using medication like
botulinum toxin injection (BTI) into the LES or dis-
rupting the LES muscle by stretching its fibers with
dilators or by dividing it surgically or endoscopically
(myotomy).15
However, over the last 10 years, there has been sig-
nificant evolution of the management of achalasia
with the introduction of new diagnostic tools as high-
resolution manometry (HRM)16,17 and treatment
options as peroral endoscopic myotomy (POEM)18,
temporary stent insertion and injection of chemical
substances in the LES.
Achalasia is a disease treated by both gastroen-
terologists and surgeons and two American scientific
societies of gastroenterologists and surgeons (ACG &
SAGES) have produced guidelines for achalasia.19,20
This new ISDE Clinical Guideline for Achalasia (I-
GOAL), however, is distinctive in that it is interdisci-
plinary and international. Our guideline aims to offer
all stakeholders (physicians and surgeons, patients,
and health policy managers) a useful and up-to-date
resource for applying the best evidence-based prin-
ciples to the diagnosis and management of acha-
lasia, and achalasia of Chagas’ disease. The guide-
line is also based on a unique interactive methodology
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that allows the development of statements on diseases
where there are few high-quality studies and scant evi-
dence to support strong recommendations.21
METHODS
All forms of achalasia (adult, pediatric, achalasia
related to Chagas disease and achalasia related to
triple A, Down syndrome, or other genetic diseases)
were considered.
The ‘Working Group’ comprised 51 members from
medical and surgical specialties and included three
patient representatives and two conveners (GZ and
DL). Participants were selected among ISDE mem-
bers with a specific interest in managing achalasia
by the two conveners. Other members of the team
included a scientific consultant who coordinated the
process and edited submitted statements (CB), and a
web developer (SG). CB and SG (non-voting group
members) initially developed the process to be applied
during the development of the guidelines. The group
was geographically diverse with members from the
USA (19), Italy (8), UK (3), Belgium (4), Australia
(2), Brazil (7), Germany (2), France (2), Netherlands
(1), Japan (1), China (1), Argentina (1). Panels were
created by inviting participants from both gastroen-
terology and surgery to work in study groups led by a
Chairperson.
We systematically searched for evidence, selected
evidence, and integrated this with three rounds of an
eDelphi process to obtain consensus on key areas:
 Diagnostic workup,
 Definition of the disease,
 Severity of presentation,
 Medical treatment,
 BTI,
 Pneumatic dilatation (PD),
 POEM,
 Other endoscopic treatments,
 Laparoscopic myotomy,
 Definition of recurrence,
 Follow up and risk of cancer,
 Management of end stage achalasia,
 Treatment options for failure,
 Achalasia in children,
 Achalasia secondary to Chagas’ disease
 Achalasia secondary to genetic diseases.
We excluded ‘secondary achalasia’ as this is not a
well-defined condition.
Our approach combined the principles of evidence-
based medicine supported by systematic literature
reviews with the use of an iterative anonymous voting
process22-24 and the method used is accredited for
guideline production by NICE UK.25 The online
platform permitted anonymous individual feedback
and changes of views during the process, together
with controlled feedback of evidence regulated by the
coordinator (CB) and the consensus chair (GZ). The
group was initially asked to identify areas where there
is uncertainty in management and to provide clin-
ical questions, structured by population, intervention,
comparator, and outcome (PICO).
Keywords identified from the clinical questions
were used to construct literature searches in electronic
databases (Appendix of search strategies),
The principal steps in the process were: (1) selec-
tion of the consensus group and identification of clin-
ical questions; (2) development of draft statements by
the panels; (3) systematic literature reviews to iden-
tify evidence to support each statement; (4) produc-
tion of evidence-based discussions using the selected
evidence; (5) 3 rounds of iterative voting and com-
menting. The initial stage was the development of
statements followed by a comprehensive literature
review. Statements were prepared that described the
population, the intervention or management strategy,
whether a comparison strategywas applicable, and the
outcomes being assessed. Participants were assigned
to panels corresponding to statements and developed
pertinent summaries for each statement using the
available literature. These summaries were written by
the panel members and included all the relevant evi-
dence identified for each statement, making specific
reference to any studies that were assessed but which
did not contribute additional evidence. The Summary
Statements were then posted online for voting and
feedback to guide refinement.
The respondents were asked to choose one of the
following for each statement; agree strongly (A+),
agree with reservation (A), undecided (U), disagree
(D) or disagree strongly (D+). Participants voted
on statements, assessments were made on the basis
of the participants’ comments and judgments were
informed of the supporting evidence. We defined con-
sensus as 80% of respondents strongly agree or agree
with reservation. When agreement was not reached,
we rephrased the statement to see if this would pro-
voke stronger agreement. If no strong agreement was
reached after at least two rounds of voting, it was
eliminated.
We electronically collected conflict of interest dec-
larations at each stage of the voting process, electron-
ically, at voting. The study is a secondary analysis of
published work and did not involve human subjects or
interventions therefore it did not require ethics com-
mittee review. However, the study was overseen by the
ISDE and was subject to the review of ISDE’s ethics
committee.
GRADE
We used the GRADE system26,27 to describe the
quality of the evidence and the strength of recommen-
dation. We used GRADE terminology for statements
and recommendations.28 The lack of effect estimates
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and potential selection bias inherent in the included
observational studies meant that much of the evidence
was very low or low-quality evidence.
Evidence from randomized controlled trial (RCT)
data is initially given a high-quality rating but is down-
graded if the study methodology has a risk of bias i.e.
there is unexplained clinically relevant heterogeneity,
evidence is indirect, there is important uncertainty
around the estimate of effect or there is evidence for
publication bias. As a result, it is possible forRCTdata
to have a very low quality of evidence if several of these
concerns are present. Evidence from observational
studies starts at low quality but can be upgraded if the
effect size is large, there is a dose response and all plau-
sible confounding would act in the opposite direction
to the effect noted. After completion of the consensus
process, we used the GRADE approach to make rec-
ommendations, producing grade profiles29 and we
quantified the strength of recommendations.30,31 A
strong recommendation suggests that the interven-
tion should be offered to most patients most of the
time whereas a conditional recommendation suggests
that there is either lower quality evidence, the bal-
ance between benefits and downsides is closely bal-
anced and/or important uncertainty about patients’
values and preferences exists. GRADE ratings were
not applied when recommendations were considered
to refer to universally accepted good practice32 rather
than evidence-based decisions on two or more com-
peting management strategies.
Systematic literature search
Three authors (MS, RS, and LF) independently
searched electronic databases MEDLINE (via
Pubmed), EMBASE, and the Cochrane Central
Register of Controlled Trials (CENTRAL) from
2000 to December 2016 for English-language articles.
Exclusion criteria included studies on esophageal
spastic motor disorders other than achalasia, case
series reporting outcomes with less than ten patients
and case reports. We used the PICO scheme to build
our search strategy using search terms describing the
patient and intervention. An updated search using
the MeSH term ‘[esophageal achalasia]’ was repeated
in December 2017 and newly published articles or
requested by participants were added to the main
database up to January 2018 which coincided with
our third and final round of voting. The references of
the included articles were hand-searched to identify
additional relevant studies. Participants were allowed
to suggest more references (also outside the original
time frame period) if they deemed them appropriate
for the study.
Prior to the first voting round, users were able to
select from this database and the convener (GZ) and
a research assistant (SM) used these bibliographies to
provide evidence-based discussions to associate with
each statement available for review by the panel. Par-
ticipants were also invited to add new literature at each
round of the process. In this way, the group identified
a list of primary references specific to each statement
and these were used to develop the statement discus-
sion. Panel chairs were responsible for the final selec-
tion of evidence and editing statement discussions,
with moderation by CB and GZ. The literature search
technique permitted inclusion of additional articles
during the consensus process that might have been
missed during initial searches (including newly pub-
lished articles added at updates). Before including arti-
cles for citation, the articles were reviewed by panel
members and the convener (GZ). GZ reviewed the
studies obtained at the updated search in December
2017 and add relevant studies to the online database;
these were then included in the evidence-based discus-
sions. Appendix 1 describes the precise search terms
used for each PICO statement and the PRISMA
search strategy and flowchart generated.
RESULTS
Literature search
Out of 3183 articles were initially retrieved (including
61 articles added with the updated 2017 search) and
128were added by the panelists; 22 articles were added
after the updated literature search in January 2018. In
total, 466 articles were considered for the preparation
of the Guidelines. A detailed PRISMA figure for each
of the key areas is provided in the online supplement
(Figs. S1–15)
We found that the overall GRADE quality of evi-
dence related to all the statements was low, or at best
moderate although the consensus process resulted
in a high level of consensus for many statements.
At the final round of consensus, we achieved con-
sensus (≥80% agreement) on 47/57 statements, 10
statements were not accepted. Of these 10, at least 50%
of the participants who voted agreed with the state-
ment, but they failed to reach consensus according
to our criteria. Two statements (on PD for treatment
of recurrence after surgery) were similar in content
and were combined for the purposes of this guideline
manuscript.
We selected, on the basis of the agreement level
and clinical relevance, 46 statements that represent
the following key clinically relevant areas: 1. Diag-
nosis of achalasia, 2. Management of primary dis-
ease; 3. Definition of failures; 4. Risk of cancer and
follow-up of achalasia patients; 5Management of fail-
ures; 6. Definition diagnosis and treatment of ‘end
stage achalasia’; 7. Management of achalasia in chil-
dren; 8. Diagnosis and management of achalasia in
Chagas disease. These 46 statements form the basis
of this guideline. All the statements were archived:
(http://www.mdpub.org/igoal).
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Diagnosis of achalasia
1. HRM is the test of choice for the diagnosis of acha-
lasia (compared to conventional manometry).
Agree: 94.2% [D + (2%); D (0); U (3.8%); A
(26.9%); A + (67.3%)]
HRM records intraluminal pressures circumferen-
tially at 1 cm intervals over a 36 cm segment along the
length of the esophagus. These pressure data are trans-
formed into a topographic color contour plot. HRM
is easier to perform than conventional manometry,
the learning curve for recognizing the color contour
patterns is shorter, and inter-rater and intra-rater
agreement for the Chicago classification of achalasia
subtypes is very good to excellent.33,34 HRM has
generated a new metric for esophagogastric junction
(EGJ) relaxation known as the ”integrated relaxation
pressure” (IRP) measured within the swallowing
window from the initiation of a swallow and Upper
Esophageal Sphincter (UES) relaxation until the
arrival of the peristaltic contraction at the LES or
after 10 seconds in absence of peristalsis. Relaxation
pressure is reported as the lowest value persisting for 4
seconds after the swallow and can distinguish between
the LES and crural diaphragm components.35 One
study found a two-fold increase in the diagnosis of
achalasia compared to conventional manometry from
12% to 26%.36 Based on a series of 62 patients with
well-defined achalasia 4-second IRP >15 mmHg as
had a sensitivity of 97% and only 3% false negative
rate. This was a considerable diagnostic improvement
over the single sensor nadir >7 mmHg, which only
had a sensitivity of 52% with a striking 48% false
negative rate.37 Despite evidence supporting the use
of HRM, this test has not yet been widely adopted,
especially in nonacademic hospitals.38
Recommendation: we conditionally recommend the
use of HRM for the diagnosis of esophageal
achalasia (compared to conventional manometry).
GRADE: low.
2. The Chicago Classification is a useful tool to define
the clinically relevant phenotypes of achalasia.
Agree: 90.4% [D + (1.9%); D (1.9%); 3 (5.8%); A
(44.2%); A + (46.2%)]
The Chicago Classification 3.0 was created to
define clinically relevant phenotypes for esophageal
motor patterns that are associated with the chief com-
plaint of dysphagia using 10 5 mL water swallows. By
utilizing the integrated relaxation pressure, specific
metrics of propagation and pressurization patterns,
the Chicago Classification 3.0 provides a system-
atic classification scheme that can define achalasia
into distinct subtypes (I, II, III) and variants that
may indicate evolving/early achalasia (EGJ outflow
obstruction) or achalasia in the context of a low LES
pressure (absent contractility).16,39 The subtypes of
achalasia are defined on the basis of the patterns
of esophageal body contractility and pressurization
once an elevated integrated relaxation pressure estab-
lishes that there is resistance to bolus transit at the
esophagogastric junction. This approach provides a
more systematic mechanism for classifying achalasia
based on an algorithm with specific criteria and a
high level of agreement between interpreters. Thus,
the Chicago Classification 3.0 is a more robust and
standardized method to classify achalasia compared
to conventional manometry and barium esophag-
raphy, which fail to distinguish patterns beyond
vigorous achalasia. This classification scheme does
not capture all achalasia patients as early achalasia
can be seen with propagating contractions and an
elevated IRP (EGJ outflow obstruction)39 and in the
late stages where esophageal dilatation occurs and
intraesophageal pressures are too low to generate an
elevated IRP in the context of absent contractility.
Type II achalasia has the best prognosis and while
type III tends to have the worst prognosis.16,40-44 Type
I may represent a more advanced stage of achalasia
and its prognosis is variable, but in general is worse
than Type II.
Recommendation: we recommend classification of
achalasia according to the Chicago Classification.
Good practice recommendation.
3. The timed barium esophagram offers an objec-
tive evaluation of the diseases and of the out-
come after treatment (compared to traditional barium
esophagram).
Agree: 90%. [D + (2%); D (4%); U (4%); A (50%);
A + (40%)
In the timed barium esophagram (also known as
the timed barium swallow (TBS)),45 the patient drinks
100–200 mL of low density (45% weight by volume)
barium sulfate over one minute in the upright posi-
tion. Frontal spot films of the esophagus are obtained
at 0, 1, 2, and 5 minutes. The height of the barium
column is measured from the distal esophagus, identi-
fied by the ‘bird-beak’ appearances of barium, to the
top of the distinct barium column. Width (diameter)
of the esophagus can be measured at the widest part
of the barium column perpendicular to the long axis
of the esophagus. The degree of esophageal emptying
is estimated either qualitatively by comparing the
barium height on images taken at 1 and 5 min or
by measuring the height and width of each image,
calculating a rough area for both and determining
the percent change in area.46 The TBS is a repro-
ducible technique for estimating esophageal emptying
with almost perfect interobserver agreement.45 TBS
predicts the likelihood of symptom recurrence after
pneumatic dilation or surgical myotomy.47 Rohof
et al. observed that the esophageal retention was a
good predictor of treatment failure in long-standing
achalasia and proposed using the TBS rather than
manometry to decide on retreatment.48 TBS is not
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yet widely adopted, however, and many centers still
use barium swallow esophagogram.
TBS studies provide data for diagnosis and to pre-
dict improvement after treatment. A 50% improve-
ment in emptying and >5 cm of stasis at 5 minutes48
were good predictors of treatment failure and recur-
rence. A recent study on 188 achalasia patients, 46
EGJ outlet obstruction, and 146 patients with dys-
phagia from other causes, based on ROC analysis,
barium column height of 5 cm at 1 minute showed the
highest sensitivity of 86% and specificity of 71%, while
the barium column height of 2 cm at 5minutes had the
highest sensitivity of 80% and specificity of 86% in dif-
ferentiating achalasia for the other two groups.49 Two
studies, however, do not support the positive prog-
nostic ability of TBS.50,51
Recommendation: we conditionally recommend the
use of TBS in the diagnostic pathway of achalasia
and to evaluate the outcome of treatment. GRADE:
low.
4. Endoscopy should be performed in patients with
suspected achalasia to exclude malignancy of the esoph-
agogastric junction.
Agree: 98.1% [D + (0%); D (0%); U (1.9%); A
(9.6%); A + (88.5%)]
Endoscopy has a low diagnostic yield52 in the diag-
nostic workup of achalasia and its primary role is
in ruling out a pseudoachalasia (secondary acha-
lasia) or mechanical obstruction.53-58 Three clinical
features are thought to be suggestive of cancer as
a cause of pseudoachalasia: short duration of dys-
phagia (<1 year), serious weight loss (>6.8 kg),
and age over 55 years. The presence of any of
these features should raise a suspicion of cancer,
even though they have a low predictive accuracy.19,59
Mucosal ulceration or nodularity, reduced compli-
ance of the gastroesophageal junction, or an inability
to pass the endoscope into the stomach are the most
common EGD findings of pseudoachalasia. Endo-
scopic biopsy is used for the diagnosis of secondary
pseudoachalasia.60-64
Recommendation: We recommend performing UGI
endoscopy in adult with the suspected diagnosis
of achalasia to exclude neoplastic pseudoachalasia.
Good practice recommendation.
5. The Eckardt score is a simple tool to measure
symptom severity in achalasia patients, but it should be
integrated with objective measures such esophagogram
and manometry.
Agree: 86.5% [D + (0%); D (2%); U (11.5%); A
(42.3%) A + (44.2%)]
The Eckardt score (ES) is a simplemeasure to assess
achalasia outcome and focuses on 4 symptom compo-
nents: dysphagia, regurgitation, retrosternal pain, and
weight loss. The 4 components are graded from 0 to 3,
and patients are classified as having a good outcome
if ES is <3 or a poor outcome if ES ≥3.65 Although
this measure is the most widely used and accepted
questionnaire for achalasia disease severity, it has not
been validated outside of comparisons with physio-
logic measures and has not been vetted as a patient
reported outcome measure.66,67 In a paper published
after the consensus process ended, it was reported that
the Eckardt score did not fulfill criteria for a validated
symptom score, and the chest pain and weight loss
components may decrease the reliability and validity
of this score.68
Recommendation: we recommend the use of the
Eckardt score as part of the initial and follow-up
assessment in patients with achalasia. Good practice
recommendation.
Treatment of achalasia
Medical treatment
6. There is no convincing evidence that medical treat-
ment with nitrates is effective for symptomatic relief in
adults with achalasia. Agree: 86.5%
[D + (3.8%); D (5.5%); U (6.9%); A (56.9%);
A + (26.9%)]
7. There is no convincing evidence that medical treat-
ment with calcium blockers is effective for (short term)
symptomatic relief in adults with achalasia.
Agree: 88.2% [D + (0%); D (2%); U (9.8%); A
(54.9%); A + (33.3%)]
8. In adults with achalasia, there is no evidence that
medical treatment with phosphodiesterase inhibitors is
effective for symptomatic relief.
Agree: 84.3% [D + (0%); D (2%); U (13.7%); A
(54.9%); A + (29.4%)]
There is no convincing evidence for using any of
these medications for short term relief of achalasia
symptoms.69-83
Recommendations: we recommend against the use
of nitrates, calcium blockers or phosphodiesterase
inhibitors treatment for symptomatic relief of acha-
lasia. GRADE: low.
Botulinum toxin injection ‘Botox’ (BTI)
9. BTI has limited application in young patients (aged
less than 50 years).
Agree: 92.3% [D + (0%); D (5.8%); U (1.9%); A
(42.3%); A + (50%)]
We found no evidence to support the use of BTI in
patients<50 years.84-90 We did not specifically address
its utility in patients under 50 years of age who are at
high-risk for surgical or other procedures.
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10. BTI should be reserved for patients who are unfit
for surgery or as a bridge to more effective therapies,
such as surgery or endoscopic dilation.
Agree: 94.3% [D + (0%); D (3.8%); U (1.9%); A
(46.2%); A + (48.1%)]
BTI in the LES in achalasia has a very high safety
profile and even mild adverse event with heartburn or
chest pain are observed in less than 10% of patients
treated.91 In a RCT comparing Heller myotomy with
BTI, the results in the 2 groups were comparable at
6 months, although symptom scores improved more
in surgical patients (82% vs. 66%). At 2-year follow-
up, only 34% of BTI patients versus 87.5% of the
Heller patients were asymptomatic.92 Similarly, four
randomized trials and a Cochranemeta-analysis com-
paring BTI with pneumatic dilations (PD) consis-
tently reported a higher cumulative rate of remission
rate at 1 year after treatment.85,86,93-96
Recommendations: we recommend against the use of
BTI in patients under 50 years of age, for control of
symptoms. GRADE: very low:
We recommend against BTI as an effective therapy
(control of symptoms) for achalasia in patients fit
for surgery (LHM) GRADE: moderate.
We recommend against BTI as an effective therapy
(control of symptoms) for achalasia in patients fit
for pneumatic dilatation GRADE: moderate.
11. Repeat treatments with BTI are safe, but less
effective than initial treatment.
We found that repeated treatments may be suc-
cessful, if there are contraindications to invasive, but
more durable treatments. BTI efficacy, however, may
decrease over time. In an open study97 followed up
35 patients treated with BTI, 12 (34.3%) relapsed and
were retreated, 4 out of 12 did not respond after re-
treatment. In a controlled trial,85 7 of the 8 patients
in the botulinum toxin group required a second injec-
tion because of recurrent dysphagia, the effect of the
second injection lasted for at least 6 months in all
treated patients, compared with only two thirds in
the trials by Pasricha in 199498 and was still evident
in 80% of this series at 1 year of follow-up. In this
study, symptoms recurred in the long-term respon-
ders about 1 year after the initial injection. How-
ever, in such patients, further injections at this stage
retained their efficacy. In a retrospective89 study of
25 patients with achalasia of the 16 patients who
responded to the initial injection, two were lost to
follow-up and in the remaining 14 patients, the out-
come was still satisfactory in nine patients after a
mean of 2.5 years. The five patients who experienced
only a short-term clinical success received a second or
third injection of botulinum toxin, but their symptoms
never improved substantially for more than 6 months.
In a pilot, open trial by Martinek in 2003,99 antero-
grade and retrograde BTIs were given. After a single
BTI, 11 responders reported a relapse and 2 patients
remained asymptomatic. The median symptom-free
interval was 17 months (range: 8–28). Five patients
with a relapse underwent BT reinjection. Three of
them remained asymptomatic and two experienced
the second relapse. After BT reinjection, the median
symptom-free interval was 16 months (range: 10–19).
All other patients with a relapse and without BT rein-
jection were treated with either balloon dilation or
surgery and remained asymptomatic.84,85,89,98,99
Agree: 82.4%, [D + (2%); D (2%); U (13.6%); A
(60.8%); A + (21.6%)]
Recommendation: we conditionally recommend that
for symptom relief, BTI injection can be safely
repeated, but clinicians and patients should be aware
that their efficacy is lower than in initial treatment.
GRADE: low.
12. There is no evidence that patients with 3 type III
achalasia should receive additional Botox injections in
the lower esophagus in addition to injections in the LES
to improve function and symptoms.
Agree: 92.1% [D + (0%); D (2%); U (5.9%); A
(68.6%); A + (23.5%)]
We found no direct evidence to support the use of BTI
in the lower esophagus in patients with type III acha-
lasia).17,91-93,100
Recommendation: we recommend against BTI in the
esophageal body, even in the presence of type III
achalasia. GRADE: very low.
13. There is no evidence that patients undergoing
repeat BTI of the LES should be treated with increasing
dosage of Botulinum toxin.
Agree: 96.1% [D + (0%); D (0%); U (3.9%); A
(56.9%); A + (39.2%)]
We found no evidence to support an increasing
dosage of (BT) when patients need retreatment.
Recommendation: we recommend against the use of
increasing (BT) dosage at retreatment. GRADE:
very low.
Pneumatic dilatation
14. In patients with achalasia, graded PD is an effec-
tive treatment in terms of improvement of symptoms and
swallowing function.
Agree: 90.4% [D + (0%); D (3.8%); U (5.8%); A
(32.7%); A + (57.7%)]
Graded PD consists of a series of dilations starting
with a 30mmballoon, and depending on the response,
followed by dilations using 35 mm and in some cases,
a 40-mm balloon. Dilation is aimed at reducing the
LES pressure in achalasia and reducing the resistance
to bolus flow with consequent improvement in symp-
toms. There is no evidence about optimum duration
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of inflation, the balloon pressure to be applied or the
interval between the successive dilations.
Graded PD is effective as an initial treatment in
terms of symptoms including dysphagia, but suc-
cess rates decline over time and retreatment may be
required. Success rates largely vary depending on
the criteria used to define success and the dura-
tion of follow-up and they are significantly increased
by allowing redilation in case of recurrent symp-
toms.101-104 In the European RCT comparing PD
versus laparoscopic Heller’s myotomy for idiopathic
achalasia, 96% of patients responded successfully to
the initial series of pneumatic dilation.105 Success rates
(intention-to-treat) dropped from 90% at 1 year to
86%at 2 years and 82%at 5 years.105 West et al. in 2002
showed a further reduction with even longer follow-
up, with success rates dropping to 60%, 50%, and 40%
in patients with a follow-up between 5 and 9 years, 10
and 14 years and >15 years.106
One quarter to one third of dilated patients
will require redilation during the following 4–5
years.101,105 An Australian study reported that 18%
will relapse by 2 years, 41% by 5 years, and 60% by
10 years.107 Furthermore, a review summarizing four
studies of patients who had two or more dilations
showed that 92%, 84%, 78%, and 64% patients were
in remission at 1, 2, 3, and 5 years.108
In comparison with surgical therapy (LHM) in a
RCT,109 the clinical response and the variables related
to good results in 92 patients with achalasia who
were randomized to receive either PD or laparo-
scopic Heller myotomy (LHM) with partial fundo-
plication were evaluated. Three months after treat-
ment, 73% of the patients from PD group and 84%
of the surgery group had good results (P = 0.19).
After 2 years of follow-up, 54% of the PD group and
60% of the surgery group (P = not significant) were
symptom free. They concluded that surgical treatment
and PD for achalasia are equally effective after 2 years
of follow-up. However, some randomized trials com-
paring PD and LHM110-112 showed better control of
the outcomes of symptom control, GERD, and dys-
phagia respectively, after LHM. For symptom remis-
sion, LHM was not superior to PD in one meta-
analysis,113 however, other meta-analyses114,115 have
shown better treatment success,114 and response rate
(control of symptoms)115 for LHM.
Recommendation: we recommend graded pneu-
matic dilatations as an effective treatment (control
of symptoms including dysphagia) for esophageal
achalasia. GRADE: moderate. Patients wishing
longer term remission (without further dilatation)
may opt for surgical treatment.
15. In patients with achalasia who have received pneu-
matic dilation, the best postprocedural test to assess if a
perforation occurred is a Gastrografin (iodine contrast)
swallow.
Agree: 80.8% [D + (1.9%); D (5.8%); U (11.5%); A
(48.1%); A + (32.7%)]
Perforation is a serious complication of PD and
should be diagnosed immediately to prevent soiling
of the mediastinum or thoracic cavity with luminal
contents. The rate of perforation after PD varies from
2% to 5.4% and is associated with patients who are
older than 65 years, high amplitude of contraction
in the distal esophagus and the use of Witzel dila-
tors.116 Perforation symptoms include epigastric pain,
chest pain, left shoulder pain, dyspnea, fever, and
moderate amount of hematemesis.117 Intake of water
will typically elicit epigastric or chest pain. Whether
all patients should undergo postprocedure X-ray of
the esophagus is unclear: one study by Zori 2016
compared elective radiological evaluation based on
clinical suspicion versus routine esophagograms in
all patients in a total population of 119 patients.118
Although only three perforations occurred, no per-
forations were missed in the group where an esoph-
agogram was taken if there was clinical suspicion
of perforation, suggesting that the radiological eval-
uation could be performed only in case of clinical
suspicion.
Recommendation: we recommend that after PD
patients are observed for 4 hours, water-soluble
iodine contrast (Gastrografin) esophagogram (or
CT scan with oral contrast) should be performed if
any symptoms, even if moderate, suggest that per-
foration is present after dilatation. We recommend
against the routine use of contrast esophagram or
computed tomography shortly after PD. GRADE:
low.
16. There is only limited evidence that pneumatic
dilatation may be used as first-line therapy in megae-
sophagus (diameter >6 cm & sigmoid shaped).
Khan et al. reported their experience in 9 patients
withmegaesophagus (>7 cmdiameter) out of 110who
underwent pneumatic dilation. In this cohort, it was
possible to dilate adequately, in all nine cases without
complications, with good symptomatic improvement
at 12-month follow-up.119 Although there are no
studies that definitively show that esophageal diam-
eter determines outcome, pneumatic dilation is con-
sidered difficult in patients with sigmoid esophagus
and associated with a higher rate of complications.
Agree: 82.4% [D + (2%); D (2%); 7 (13.6%); A
(66.7%); A + (15.7%)]
Recommendation: we make no recommendation
about pneumatic dilatation as first line therapy in
megaesophagus. GRADE: very low.
17. There is no evidence that patients undergoing
graded dilation should be treated with proton pump
inhibitors as maintenance therapy after the proce-
dure, unless symptomatic or positive at 24-hour pH-
monitoring.
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There are several studies which report on the
development of GERD-related disease following
pneumatic dilation and other treatments.105,112,120-123
However, none of these studies provided information,
which would result in all patients being treated pro-
phylactically with acid suppressive therapy after such
interventions. The utility of wireless pH monitoring
to detect GERD was confirmed in a case series, (not
included in our initial assessment of the literature).124
In such cases, or when symptoms are present, PPI
therapy should be offered. In conclusion, none of the
examined studies reported the necessity on using PPI
after PD as prophylaxis but given the high risk of
GERD in such patients, the threshold for suspecting
it should be low and PPI should be prescribed when-
ever symptoms occur, or GERD is confirmed by pH
monitoring.
Agree: 94.3 [D + (0%); D (1.9%); U (3.8%); A
(63.5%); A + (30.8%)]
Recommendation: we recommend against the pro-
phylactic use of PPI after PD, unless GERD symp-
toms are present or objective evidence of reflux is
demonstrated124 GRADE: very low.
Peroral endoscopic myotomy
18. Treatment of achalasia patients with POEM,
results in similar outcomes on swallowing functions
compared with alternative treatment (Heller myotomy
or pneumatic dilation), at least at medium-term follow-
up (2–4 years).
Agree: 88.4 % [D + (0%); D (5.8%); U (5.8%); A
(55.8%); A + (32.6%)]
The efficacy of POEM procedure has been mainly
evaluated with changes in the Eckardt score to assess
symptom improvement and timed barium esopha-
gogram and manometry to assess the functional out-
comes. Published studies report therapeutic success
in 82–100% of patients, with dramatic reductions in
the Eckardt score as well as the LES pressure.37,125,126
Medium-term outcomes for POEM are now available
in the literature with the longest follow-up now at
5 years.127 The NOSCAR white paper128 reports an
>82% clinical success rate among 16 expert centers
(841 patients) and a meta-analysis of 1122 patients
shows a pooled overall failure rate (Eckardt >3)
between 3.2% and 8%.128–130 While there are multiple
institutional and pooled retrospective comparisons
between LHM and POEM,130-136 there have been no
comparable comparisons between POEM outcomes
and achalasia balloon dilation other than an abstract
of a RCT, (which was not included in our initial liter-
ature review as it was an abstract), with 133 patients
who were therapy-naı¨ve randomly assigned to POEM
or PD, and which showed higher 1 year therapeutic
success in the POEM group.137 Most authors make an
indirect inference to the relative equivalence of PDand
LHM.
Comparative studies between POEM and LHM
have uniformly shown equivalence or slight superi-
ority to POEM in most intraoperative or postopera-
tive domains.131,133,135 Zhang et al. recently reported
the outcome of POEM in a cohort of 33 patients
with type III achalasia: at a median follow-up of
27 months 29 patients (87.8%) were asymptomatic
with an Eckardt score >3.132 Guo et al. analyzed the
long-term outcome of POEM in 67 patients (mean
follow-up: 40.1 ± 2.8 months) and reported a good
symptomatic result (Eckardt score <3) in 59 patients
(88%).138 However, patients with type III achalasia
were more likely to experience treatment failure. To
date there is still insufficient evidence that POEM
results in similar improvement in function and symp-
toms in all achalasia subtypes due to the paucity of
data, short follow-up period, and lack of objective
postoperative esophageal testing.139
Recommendations: we conditionally recommend
POEM as an effective therapy (control of symp-
toms) for achalasia both in short- and medium-term
follow-up with results comparable toHellermyotomy
for symptom improvement. GRADE: very low.
We conditionally recommend POEM as an effective
therapy (control of symptoms) for achalasia both in
short- and medium-term follow-up with results com-
parable to pneumatic dilations for control of symp-
toms. GRADE: low
19. Treatment of achalasia with POEM is associated
with a higher incidence of GERD compared to alterna-
tive therapies (Heller myotomy with fundoplication or
pneumatic dilation).
Agree: 96.2% [D + (0%); D (1.9%); U (1.9%); A
(46.2%); A + (50%)]
When performing surgical myotomy of the LES
both the longitudinal and the circular fibers are
divided, and a partial fundoplication is typically
added to prevent gastroesophageal reflux (Dor or
Toupet procedure). This raises the question if POEM
is associated with high incidence of postopera-
tive GERD. Outcome data regarding the incidence
of GERD after POEM are currently limited. The
NOSCAR2015 white paper on POEMcites 12 studies
with only 3 reporting pH monitoring data, on objec-
tive testing, the rate of GERD after POEM was
20% to 46%.140 Patel in 2016 reviewed 22 studies (19
case series and 3 comparative studies) and reported
only two additional studies that employed esophageal
ambulatory pH monitoring in POEM. One study on
41 patients demonstrated GERD in 4/13 (30.7%) and
another study on 100 patients documented GERD in
39/73 (53.4%).130 Bhayani in 2014, however, reported
on 101 patients who underwent postoperative 24-
hour pH testing following Heller (48%) and POEM
(76%).131 Postoperatively, 39% of POEM and 32%
of HM had abnormal acid exposure (P = 0.7).
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Inoue reported on their series of 500 patients (no
pH monitoring) and demonstrated that 268 of 414
patients (64.7%) had endoscopic findings of reflux
esophagitis and (16.8%) complained of GERD symp-
toms such as heartburn or regurgitation.127 In a
multicenter trial of 205 patients in total,37 of 197
patients with available clinical data, 18%% had reflux
esophagitis after POEM and 37.5% had abnormal
esophageal acid exposure.141 A systematic review by
Schlottmann142 compared data between LHM and
POEM and showed that while POEMwas more effec-
tive in relieving dysphagia, the patients were more
likely to develop GERD symptoms (OR 1.69, 95%
CI 1.33–2.14, P < 0.0001), GERD related erosive
esophagitis (OR 9.31, 95% CI 4.71–18.85 P < 0.0001,
and abnormal pHmonitoring (OR 4.30, 95%CI 2.96–
6.27, P < 0.0001).141,143,144
Recommendation: Pretreatment information on the
risk of GERD should be provided to the patient and
follow-up acid suppression therapy) considered after
POEM. Good practice recommendation.
Patients who seek a nonsurgical treatment (PD) or
surgical treatment with a lower incidence of postpro-
cedure GERD (Heller myotomy) should be coun-
seled that these options exist.
20. There is no evidence that previous treatment of
patients with achalasia with pneumatic dilation or BTI
reduces the technical feasibility of POEM and results
in poorer outcomes.
Agree: 86.6% [D + (0%); D (1.9%); U (11.5%); A
(71.2%); A + (15.4%)]
Technical feasibility of POEM and outcome after
dilatation or BTI treatment have never been specifi-
cally addressed by a prospective study. There are case
series145-150 reporting on patients with prior PD or
BTI. These studied the outcomes and/or technical dif-
ficulty of POEM in those cases to achalasia patients
without prior treatment. All of them reported that
previous treatment did not affect the performance or
early outcome of POEM.
Recommendation: we recommend POEMas feasible
and effective for symptom relief in patients previously
treated with previous endoscopic therapies. Condi-
tional recommendation; GRADE: very low.
21. POEM is an appropriate treatment for symptom
persistence/recurrence after laparoscopic myotomy.
Agree: 88.2% [D + (0%); D (7.8%); U (4%); A
(64.7%); A + (23.5%)]
There are several studies that have examined the
use of POEM in the treatment of recurrent achalasia
after the failure of an initial intervention: these studies
demonstrate that POEM is effective after initial failed
intervention with minimal complications; the sample
size in each individual study has been typically small
(typically 2 to 3 patients).140,148,151 In studies specif-
ically identifying patients with failed LHM, positive
outcomes and minimal complications with POEM as
second-line intervention were observed.
In a case study of 12 patients with failed LHM
undergoing POEM as second-line treatment, 91.7%
had improvement of dysphagia based on the Eckardt
score.152 In a recent retrospective multicenter cohort
study of 180 achalasia,37 a significantly lower pro-
portion of patients in the HM group had a clin-
ical response to POEM (81%) than in the non-HM
group (94% P = 0.01). POEM may be less effec-
tive as a second-line treatment after LHM than in
naı¨ve patients but remains a viable option after failed
LHM.153,154
Recommendation: we conditionally recommend the
use of POEM for symptom relief, as an option for
treating recurrences after LHM. GRADE: low.
22. Attaining proficiency with the POEM proce-
dure involves a stepwise approach to education and a
defined learning curve for both medical and surgical
endoscopists.
Agree: 90.2% [D + (0%); D (0%); U (9.8%); A
(25.5%); A + (64.7%)]
POEM is a complex procedure that requires mas-
tering specific endoscopic skills and understanding
certain visual cues to completely and safely achieve an
appropriate myotomy. The current literature is limited
and definition of a minimal learning curve with cur-
rent recommendations ranging between 7 and 40 pro-
cedures is needed to achieve proficiency.155-158 Preclin-
ical training using videos, experience using cadaver or
animalmodels, observations of human cases andmen-
toring by experts have all been recommended when
introducing POEM in clinical practice (NOSCAR
2014).129
Recommendation: appropriate training with in vivo
/ in vitro animal model and adequate proctorship is
recommended before starting a clinical program of
POEM. Good clinical practice.
Alternative treatments: retrievable stents and intrasphinc-
teric injection with ethanolamine oleate or polidocanol
23. There is little evidence to support that modified
retrievable stent placement at the LES is an effective
treatment for patients with achalasia.
Agree: 98% [D + (0%); D (0%); U (2%); A (52.9%);
A + (45.1%)]
24. There is no or little evidence to support the use of
endoscopic sclerotherapy with ethanolamine oleate or
polidocanol as an effective first treatment for patients
with achalasia.
Agree: 96% [D + (0); D (0); U (5.8%); A (29.4%);
A + (66.6%)].
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Despite the number of studies retrieved in our
searches, there is no convincing evidence for using
any of these treatments for relief of achalasia
symptoms.159-171
Recommendation: We recommend against tempo-
rary (retrievable or absorbable) stents and intras-
phincteric injection with ethanolamine oleate or poli-
docanol for achalasia. GRADE: low.
Laparoscopic Heller myotomy
25. The best outcomes for LHM are achieved in
(Chicago) type I & type II achalasia patients.
Agree: 90.4% [D + (0%); D (3.8%); U (5.8%); A
(46.2%); A + (44.2%)]
A meta-analysis of three randomized controlled
trials105,110,112 found that LHMwas significantlymore
effective than PBD after 12-month follow-up.115
Type II achalasia patients were significantly more
likely to respond to pneumatic dilatation and LHM
(100%), as compared to type I (56%) and type III
(29%).17 In 246 consecutive patients who underwent
LHM and found that treatment failure rates were
significantly different among the subtypes of acha-
lasia: type I 14.6%, type II 4.7%, and type III 30.4%
(P= 0.0007).41 In a post-hoc analysis of the European
RCT, a higher percentage of patients with type II acha-
lasia were treated successfully with PD or LHM than
patients with type I or III achalasia.40 Both LHM and
PDhave a lower effectiveness in type III, but LHMhas
a better outcome of PD in type III. This was confirmed
by a meta-analysis encompassing nine observational
studies, and 727 patients which showed that type II
achalasia was associated with the best prognosis after
LHM, while type III achalasia had the worst prog-
nosis: ‘The pooled OR between the subtypes of acha-
lasia after PBD or LHM showed that the best and
worse treatment outcomes were found in patients with
type II and III achalasia, respectively (type I vs. type
II after PBD: OR 0.16, 95% CI 0.08–0.36, P = 0.000;
type I vs. type III after PBD: OR 3.64, 95% CI 1.55–
8.53, P = 0.003; type II vs. type III after PBD: OR
27.18, 95% CI 9.08–81.35, P = 0.000; type I vs. type
II after LHM: OR 0.26, 95% CI 0.12–0.56, P= 0.001;
type I vs. type III after LHM: OR 1.89, 95% CI 0.80–
4.50, P = 0.148; type II vs. type III after LHM: OR
6.86, 95% CI 2.72–17.28, P = 0.000).’172
‘Spastic’ forms of achalasia (Type III according to
the Chicago classification) are rare and they represent
approximately 10 to 15% of all patients with acha-
lasia; there are no specific trials comparing other treat-
ments to LHM in type III. All the trials comparing
PD to LHM consistently show that LHM is at least
as effective as PD, and that this effect is durable (5-
year follow-up)111 and three meta-analyses 114,115,172
suggest that LHM is even more effective than PD,
meaning that in 90% of achalasia patients LHM is
very effective.
Recommendation: we recommend laparoscopic
Heller myotomy for control of symptoms in Chicago
type I and type II achalasia. Strong recommenda-
tion. GRADE: moderate.
26. Laparoscopic Heller myotomy should include a
myotomy 6 cm into the esophagus and 2 to 3 cm into
the stomach as measured from the GEJ, for effective
symptom control in achalasia patients.
Agree: 94.2% [D + (2%); D (0%); U (3.8%); A
(40.4%); A + (53.8%)]
The primary aim of surgical myotomy is to divide
the muscle bundles of the LES complex, to reduce the
esophageal outflow obstruction.16,173,174 Anatomical,
and physiological studies using manometry and endo-
scopic ultrasonography or in combination showed
that the EGJ muscle complex and the sling fibers con-
tribute substantially to the high-pressure zone and
should therefore be included in the myotomy.174,175
The need to perform an adequate myotomy distally
onto the stomach should be emphasized.176,177 (The
most appropriate length of the myotomy may depend
on the direction in which it is performed: the sling
fibers have a different width on the left and right
gastric sides of the cardia, and slightly diverting the
myotomy leftward (as is normally done), in the nar-
rower portion, ensures that most of the bundles con-
stituting the sling fibers are divided with a myotomy
2 cm long.173-178 Two studies supported extending the
myotomy up to 3 cm in the stomach and claimed a
reduction of dysphagia recurrence in patients.179,180
The proximal extent of the myotomy during LHM is
typically 6 to 8 cm cephalad to the EGJ, but no study
has compared outcomes between differential proximal
myotomy lengths.174 This proximal extent is typically
the maximum length that can be safely achieved via a
laparoscopic, transhiatal approach, but has little phys-
iologic basis, as the high-pressure zone of the EGJ
complex is on average less than 4 cm in total length,
with less than 2 cm lying cephalad to the squamo-
columnar junction.
Recommendation: we conditionally recommend
that Laparoscopic Heller cardiomyotomy should be
extended at least (6 cm proximal to the GEJ and at
least 2 cm distal to the GEJ. GRADE: low.
27. Partial fundoplication should be added to laparo-
scopic myotomy in patients with achalasia to reduce the
risk of subsequent gastro-esophageal reflux.
Agree: 94.2% [D + (0%); D (2%); U (3.8%); A
(21.2%); A + (73.1%)]
Symptomatic gastroesophageal reflux has been
reported to occur in up to 48% of patients after
myotomy for achalasia.143,180-187 While some studies
advocated a Nissen (360◦) fundoplication after
myotomy,184,185 there is a general consensus that a
complete 360◦ wrap can lead to an increased rate of
postoperative dysphagia.186-189 A RCT comparing
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anterior partial fundoplication (Dor) versus 360◦ fun-
doplication (Nissen) confirmed that the recurrence
rate of dysphagia was significantly higher among
patients who received a 360◦ fundoplication without
a significant difference in reflux control.190 There is
no consensus regarding the choice between anterior
Dor (180◦) and posterior Toupet (270◦) (partial)
fundoplications.191-193
Recommendation: we recommend that a partial
(posterior or anterior fundoplication) but not a com-
plete 360◦ wrap should be added to reduce the long-
term risk (5years) of developing gastroesophageal
reflux and dysphagia after myotomy. GRADE: mod-
erate.
28. Laparoscopic Heller myotomy with a partial fun-
doplication is as effective at improving swallowing func-
tion as laparoscopic Heller myotomy alone.
Agree: 82.7% [D + (7.7%); D (3.8%); U (5.8%); A
(36.5%); A + (46.2%)]
Laparoscopic cardiomyotomy (Heller’s procedure)
with antireflux fundoplication has been shown to
result in effective relief of dysphagia symptoms with
a low incidence of postoperative GERD resulting in
an improved quality of life and the relief of dysphagia
is not hampered by the addition of a partial fundopli-
cation.192,194,195 LHM was compared with LHM and
Dor anterior partial 180◦ fundoplication in a RCT;
therewere no differences in the baseline characteristics
between study groups. Pathologic gastroesophageal
reflux occurred in 10 of 21 patients (47.6%) after LHM
and in 2 of 22 patients (9.1%) after LHM plus Dor
fundoplication (P = 0.005).143 The Eckardt postop-
erative dysphagia score and the postoperative resting
and nadir pressure of the LES were similar in the two
groups. A systematic review195 compared the safety
and efficacy of endoscopic and surgical treatments
for esophageal achalasia. Other studies assessing the
same issue have shown that the incidence of postop-
erative GER was lower when a fundoplication was
added to a laparoscopic myotomy (31.5% without a
fundoplication versus 8.8% with; OR 6.3; 95% CI, 2.0
to19.4; P = 0.003) and the control of dysphagia was
similar.177,191,195-198,193,199
Recommendation: we recommend a partial fundo-
plication should be used when performing Heller
myotomy to prevent subsequent development of
gastro-esophageal reflux without compromising the
adequate control of dysphagia.
We recommend against LHM alone due to the risk
development of gastro-esophageal reflux. GRADE:
High.
29. LHM (or other therapies such as POEM or PD)
should be considered as the first-line treatment option in
achalasia patients with sigmoid esophagus (compared to
esophagectomy).
Agree: 86.5% [D + (0%); D (0%); U (13.5%); A
(42.3%); A + (44.2%)]
A severely dilated and sigmoid-shaped esophagus
is considered the final endpoint associated with long-
standing untreated esophageal achalasia or the result
of recurrences after failure of previous treatments. In
these patients, esophagectomy is considered a defini-
tive treatment, but this option carries a high mor-
bidity and an increased risk of mortality. Some studies
have shown good results of LHM even in advanced
phase of the disease suggesting that esophagectomy
should be reserved for patients who have failed car-
diomyotomy and other interventions.144,200-203 Mineo
et al. reported their experience in six patients and
LHM proved to be effective in improving subjec-
tive, objective, and quality of life outcome measures
in patients with sigmoid esophagus.200 In a larger
series of 33 patients with sigmoid achalasia, Faccani
et al reported that LHM was effective in relieving
dysphagia in these patients.202 Sweet and colleagues
showed that the outcome of LHM was not influenced
by the degree of esophageal dilation.203 Excellent or
good results were obtained in 91% of patients, and
none required esophagectomy. More recently, Pan-
chanatheeswaran et al. showed that LHM provided
significant improvement of dysphagia, regurgitation,
and quality of life in a small study of eight patients
with sigmoid esophagus.201 The results of LHM in
such patients are not as good as in less advanced dis-
ease.177 Occasionally, a good outcome of POEM in
sigmoid esophagus has been reported, but the experi-
ence level with this approach is low since the procedure
in this setting is technically difficult.204
Recommendation: we conditionally recommend
standard endoscopic or surgical therapies in surgi-
cally naı¨ve achalasia patients with sigmoid-shaped
esophagus, leaving esophagectomy as secondary
option in case of failure of first line therapy.
GRADE: very low.
Recurrence of achalasia after treatment
30. Symptom improvement is the most relevant clinical
parameter for defining the success of surgical or endo-
scopic treatment for achalasia.
Agree: 90.4% [D + (0%); D (3.8%); U (5.8%); A
(57.7%); A + (32.7%)]
The aim of therapy in achalasia is to palliate the
symptoms of dysphagia and regurgitation. Therefore,
symptom scores have been introduced to assess out-
comes of such treatments, including BTI, PD (PD),
surgical (LHM) or endoscopic myotomy (POEM).
The most widely used is the Eckardt score.205 Ade-
quate relief of patients’ symptoms (i.e., a good treat-
ment outcome) is usually defined by a decrease in
the Eckardt score to 3 or less, whereas a score
higher than 3 is usually associated with treatment
failure.105,141,206,207 Some authors have also used a less
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strict definition for failure by setting the threshold
level for failure to 4,207 or have used different symptom
scores,111,177,208-211 none of which have been widely
accepted.
Recommendation: we recommend assessment of
symptomatic improvement as the best measure of
success after treatment of achalasia. Good practice
recommendation
31. In adults with achalasia, there is no universal def-
inition of failure after any treatment.
Agree: 88.4% [D + (0%); D (5.8%); U (5.8%); A
(59.6%); A + (28.8%)]
Achalasia recurrencemay occur after any treatment
although with variable rates.42,65,99,101,102,104,212-226
Achalasia recurrence is defined as the develop-
ment of symptoms compatible with achalasia after
initial improvement resulting from an endoscopic
(BTI, PD, peroral esophageal myotomy (POEM))
or surgical intervention (laparoscopic or open
myotomy).42,214,227 Possible etiologies of recurrent
symptoms include scarring across the myotomy, an
incorrect or too tight fundoplication, GERD, peptic
stricture, end-stage achalasia, and malignancy.228
Many reports do not differentiate between persis-
tence and recurrence of symptoms by separating
patients who have experienced initial improvement
from those whose symptoms never sufficiently
improved.227,229,230 Moreover persistence or recur-
rence of symptoms is differently defined in some
cases as an Eckardt score that fails to fall to 3 or less
with treatment or increases to >3 following initial
successful therapy.42,231 Others have used failure to
reduce a symptom score by at least 50%.232 A thor-
ough evaluation of such patients is performed with
esophageal manometry, upper endoscopy, contrast
esophagraphy,153,229,233-235 and sometimes computed
tomography and/or esophageal pH testing.154,228
These are important to document and quantify symp-
toms of recurrence, although there is no universal
definition of failure of treatment.
Recommendation: see next statement.
32. Recurrent symptoms after achalasia treatment
should routinely undergo repeat objective testing.
Agree: 100% [D+ (0%);D (0%);U (0%); A (34.6%);
A + (56.4%)].
Symptoms are typically interpreted in the frame-
work of a standard scoring system originally designed
for assessment of untreated achalasia.65 However,
recurrent symptoms may be more etiologically com-
plex and difficult to interpret, and a standard scoring
system may fail to adequately account for other com-
ponents such as acid reflux101,104,212,213,215-219 or dif-
ferentiate recurrent achalasia from a peptic stricture.
A careful evaluation of the nature of the recurrent
symptoms, aimed at understanding the physiology
and anatomy, by means of upper endoscopy, manom-
etry, and a contrast esophagraphy is required before
the diagnosis of recurrent achalasia is made.104,153,228
A correct diagnosis of recurrent achalasia provides the
foundation for the decision as to whether the rein-
tervention is indicated, and the type of intervention
in order to accomplish a high success rate. The deci-
sion to investigate further should be balanced care-
fully with potential risks and costs of further inves-
tigations. For example, patients undergoing first PD
after confident diagnosis of achalasia may need a
second dilatation (35 mm) and it may be logical to
proceed with that, before undertaking further inves-
tigation.104,153,227,228,233,236,42,65,99,101,102,212-226
Symptom recurrence is not necessarily related to
failure of achalasia therapy, and evaluation is required
to determine the etiology of such symptoms. Recur-
rent symptoms may indicate recurrence of achalasia,
but since no universal definition of recurrent achalasia
exists and given the complexity of the disease, objec-
tive tests are warranted. Note: persistent symptoms
such as those which persist after initial PD may be
viewed differently and patients could proceed to the
second dilatation before investigations.
Recommendation: we recommend objective testing in
patients who suffer recurrent symptoms after treat-
ment of achalasia including UGI endoscopy, barium
swallow, manometry, and 24-H pHmonitoring. Good
practice recommendation
33. The timed barium swallow objectively demon-
strates the failure of achalasia treatment in patients
with persistent/recurrent symptoms.
Agree: 82.7% [D + (1.9%); D (5.8%); U (9.6%); A
(55.8%); A + (26.9%)]
Several reports have confirmed the usefulness
of the TBS as the best assessment of failure
after treatment of achalasia with botulinum
toxin,237 PD,154,229,230,235,238 Heller myotomy,235
or POEM.154,230 Vaezi et al.232 showed that TBS
was a better predictor of long-term success after PD
than symptom assessment, but recent study by van
Hoeij did not support this finding.239 Other studies
have also questioned the value of TBS for predicting
recurrence.123
Recommendation: we conditionally recommend TBS
as a reliable method to assess recurrence of acha-
lasia. GRADE: Low
Risk of cancer
34. Achalasia patients carry a moderately increased
risk of development of squamous esophageal cancer 10
years or more from the primary treatment of achalasia.
Agree: 86.5% [D + (1.9%); D (5.8%); U (7.7%); A
(61.5%); A + (25%)]
There has been an historic association between
esophageal achalasia and cancer. Two early studies
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reported a high percentage of patients with achalasia
dying of esophageal cancer (6 out of 125, 5%) or
developing cancer during a 5-year follow-up (4 out
of 124, 2%), with a 140-fold increased risk of devel-
oping cancer.106,240 Inmore recent and better designed
studies, the risk of cancer appears to be only 10 to 50
times higher compared than seen in the general popu-
lation.177,241,242
Esophageal cancer may arise from the chronic
inflammation of the esophageal mucosa due to food
debris and saliva stasis, especially in presence of sub-
optimal treatment. Hypothetically, this inflammation
will lead to epithelial hyperplasia, dysplasia, and even-
tually to squamous cancer. An alternative etiology is
that the posttreatment gastroesophageal reflux causes
the development of Barrett’s esophagus and adeno-
carcinoma.121,243,244 One large Dutch study on 448
patients (who underwent primary treatment pneu-
matic dilatation) with a follow-up of 15 years, showed
an increased risk for esophageal cancer of 28 (CI 17–
46). The majority of these cancers (12) were squa-
mous, except three adenocarcinomas.245 Two studies
examined the mortality for esophageal cancer in acha-
lasia patients: the first study was conducted in Italy
and involved the follow-up of a single-center cohort of
229 patients treated with Heller myotomy (follow-up
12 years). The second study was conducted in Sweden
on a national cohort of 2897 achalasia patients with
a mean follow-up of 9.9 years.242,246 Despite their
relatively short follow-up, both studies reported a
similar increase in the standardized incidence ratio
of death for esophageal squamous cancer only in
males of 11 (95% CI 1.33–39.7) and 13.8 (95% CI
8.1–20.4), respectively. The incidence of cancer in
the Swedish study did not vary with different treat-
ments approaches; and the excess risk was limited
to squamous cancer. Pertinently, there was a long
interval reported in all these studies between the
diagnosis/mortality for esophageal cancer and the
initial treatment of achalasia. Although we found
no evidence about routine endoscopy in this group
of patients, endoscopy may be used on a single
patient basis and/or in case of suboptimal control of
symptoms.
Recommendation: we recommend that achalasia
patients should be informed that a moderately
increased risk of esophageal cancer is present in male
after at least 10 years from the initial treatment of
the disease. Good practice recommendation.
We make no recommendation about routine
endoscopy surveillance or endoscopy intervals after
any treatment.
Management of treatment failures
35. Patients with achalasia who do not respond to ini-
tial treatment with graded pneumatic dilation, should be
referred for Heller myotomy or POEM.
Agree: 94.2% [D + (0%); D (0%); U (5.8%); A
(32.7%); A + (61.5%)]
In general, patients with achalasia have an excel-
lent response to graded PDs;1,101 when symptomatic
recurrence after graded PD occurs, and if patients are
fit for surgery, Heller myotomy is effective.15,19,104,247
However, Snyder et al. compared the failure rates of
laparoscopic Heller myotomy in patients who under-
went no or only one preoperative endoscopic inter-
vention compared tomultiple interventions.247,248 The
incidence of surgical failure was 7% in the first group
compared to 28% in the latter. Finley et al. performed
a multivariate regression controlling for age and sex
and showed that the preoperative dilation and injec-
tion of botulinum toxin were associated with signif-
icantly worse late postoperative dysphagia.249 In a
large series of 400 patients treated with laparoscopic
Heller myotomy, success rates were lower if patients
had prior endoscopic treatment of either both BTI or
PD albeit not statistically significant.177 Finally, in a
series of 200 LHM patients,250 multivariate analysis
identified an increased failure in patients with prior
endoscopic treatments (17% vs. 4%). It is however
unclear from these studies to what extent previous
botulinum toxin or PD is responsible for this reduc-
tion in the success rate.
Recommendation: we conditionally recommend that
in patients who are fit for surgery and have symp-
tomatic recurrences after several pneumatic dila-
tions, Heller myotomy, or POEM should be consid-
ered. GRADE: of evidence low.
36. Laparoscopic esophageal myotomy is a safe,
feasible, and effective treatment after failed BTI for
achalasia.
Agree: 96.2% [D + (0%); D (0%); U (3.8%); A
(38.5%); A + (57.7%)]
BTI in the LES is a safe and effective treatment
for esophageal achalasia, but its effect is not durable.
PDs,251 LHM, and POEM may be used in patients
with recurrences after BTI. In a study comparing
BTI and LHM,92 10 out of 25 patients with recurrent
symptoms after BTI were treated with LHM, with
good results in 9. It must be emphasized that some
reports have shown that LHM after BTI is more diffi-
cult,252,253 leading to higher incidence of intraopera-
tive complications including mucosal injury although
these findings were not confirmed by others.254,255
Less satisfactory outcomes were reported in patients
undergoing LHM after BTI,253,256 as compared to
patients undergoing surgery as primary treatment.
In another study,255 the logistic regression analysis
showed that prior treatment with two BTI sessions,
or the combination of BTI with PD, were signif-
icantly associated with unsatisfactory outcomes
after subsequent surgery. In conclusion, LHM is
effective treatment after failed BTI but prior BTI may
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affect outcomes and the incidences of perioperative
complications.
Recommendation: we conditionally recommend
LHM as an effective therapy for symptom recur-
rence after primary treatment with BTI. GRADE:
very low.
37. PD, compared with repeat myotomy or POEM,
is the first option for treatment after failed Heller
myotomy for achalasia.
Agree: 80.8% [D + (0%); D (5.7%), U (13.5%); A
(59.1%); A + (21.7%)]
Following LHM, 10–20% of patients with achalasia
will relapse in the mid- to long-term and need fur-
ther treatment. There is no consensus in the literature
on the best way to approach these patients: PD, BTI,
POEM, redo-myotomy, or even esophagectomy have
all been reported.
PD is safe and effective in relieving achalasia
symptoms after failed myotomy in 50% to 95% of
patients.223,236,257-261 All these reports were retrospec-
tive and were limited in the number of treated patients
(12 to 30 cases). In a large series of 400 patients, there
were 39 failures of LHM treated with PD. Patients
received 2 or more PDs. The success rate was 75%.177
This success rate is still lower than rates reported
in patients treated with PD as primary treatment
(50% to 67% vs. 74% to 86%),90,104,259 in spite of the
more frequent use of the 4.0 cm dilator. The best
success rate (78% to 95%) was reported by adopting
an ‘on demand’ dilation protocol, by offering fur-
ther PD on relapse.223,236,257 In all reported series,
the procedure was very safe with no perforations.
In 2017 Schlottmann et al. reported their experi-
ence treating patients after failure of LHM: of the
19 patients with LHM failure 12 responded to PDs
(63%) and 4 to PD and BTIs (20%); overall, 84% of
the patients were successfully managed by endoscopic
treatments.262 Comparing patients treated with PD
after failed myotomy to patients directly undergoing
additional surgery showed that the efficacy of PD
and redo-surgery in treating symptoms and improving
esophageal emptying (as evaluated by timed barium
swallow) were similar.90 In comparison, Ngamrueng-
phong et al. reported on 90 patients with failed LHM
treated by POEM and demonstrated clinical success
rate in 81% of patients.37 Therefore, PD is a safe and
effective treatment of recurrence after LHM(although
to a lesser degree than in patients undergoing primary
dilation treatment), therefore it is reasonable to offer
the patient this possibility before planning more inva-
sive therapies as LHM or POEM.
Recommendation: we conditionally recommend
pneumatic dilation as a safe and effective treatment
of symptom recurrences after LHM. GRADE: Low
38. There is insufficient evidence that the laparo-
scopic myotomy or re-do POEM offer better results
than pneumatic dilations after failed POEM.
Agree: 82.4% [D + (0%); D (5.8%); U (11.8%); A
(66.7%); A + (15.7%)]
Recurrent or persistent symptoms following POEM
do occur and there is no general agreement as to
how these relapsing patients should be managed. One
recent paper from Shanghai234 reported on 15 patients
with recurrent symptoms after POEM (Eckardt score
>3), (1% of 1454 patients in whom POEM was
performed). All 15 were treated with repeat POEM
as salvage therapy. Relief of symptoms at 11 ± 6
months was reported in all the patients expressed as
mean Eckardt score decreasing from 5.6 ± 1.1 to
1.2 ± 1.1. In two European and 1 North-American
tertiary-care hospitals, evaluating patients enrolled in
ongoing trials,227,263 43 patients with recurrent symp-
toms after POEM were identified, representing 9.8%
of 441 treated patients. PDs up to 35 mm were per-
formed in 15 of these patients with effective outcomes
seen in only 3. Further dilations with a 40-mmballoon
were not effective. Eight patients underwent a repeat
POEM, which was effective in 5, and 11 underwent
rescue LHM, that was effective in 5. Although these
numbers failed to reach statistical significance for the
small sample size, PD showed poor efficacy in treating
patients with a failed POEM, as compared to LHM
or redo POEM. After a failed POEM, repeated treat-
ment with a new POEM or LHM appears to be better
options than PD. It should be noted, however, that
most studies highlighted that repeated POEMmay be
technically demanding, due to fibrosis from the initial
treatment.227,263
Recommendation: we make no recommendation
about laparoscopicmyotomy or redoPOEMoffering
better symptomatic relief than pneumatic dilations
after failed POEM. Further research is recom-
mended to provide high quality data and guide clin-
ical decisions.
Diagnosis and treatment of end stage achalasia
39. Barium swallow esophagram, compared with
manometry, is the best diagnostic method for
defining end stage achalasia (i.e. that which requires
esophagectomy).
Agree: 94.1% [D + (2%); D (2%); U (2%); A
(59.5%); A + (34.6%)]
Barium esophography provides the best infor-
mation regarding esophageal anatomy associated
with end-stage achalasia. Anatomic features are
better appreciated on esophagogram as compared
to endoscopy and include assessment of esophageal
diameter, retention of food and saliva, a sigmoid
appearance of the esophageal body and a sump-
shaped portion of the distal esophagus and of the
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gastroesophageal junction.264 The presence of exten-
sive esophageal debris may also signal the need
for drainage and anesthesia assistance prior to
endoscopic evaluation. Several reports have utilized
barium studies to assess end-stage achalasia and indi-
cate the need for esophagectomy.265-267 Other tests
had only a secondary role in defining end-stage acha-
lasia, for example, endoscopy to assess for stasis
esophagitis, reflux stricture, or cancer.264-266 Manom-
etry may prove difficult because of the technical chal-
lenges with insertion in a dilated, tortuous, fluid, and
food filled esophagus.268
Recommendation: we recommend the use of barium
swallow as the most accurate investigation to
properly define end-stage achalasia. Good practice
recommendation.
40. Esophagectomy is indicated in patients with per-
sistent or recurrent achalasia after failure of previous
less invasive treatments (PD, POEM, LHM) and radi-
ologic progression of the disease.
Agree: 80.8% [D + (0%); D (3.8%); U (15.4%); A
(40.4%); A + (40.4%)]
When all conservative strategies failed, esophagec-
tomy is the last resort to manage achalasia.
Esophagectomy is associated with a high rate of
complications and surgical mortality rate. All effort
must therefore be focused on managing patients with
recurrent symptoms after surgery with less invasive
treatments, such as POEM or repeated myotomy
or ‘on demand’ PD. However, patients should be
carefully followed up to promptly identify when
esophagectomy is necessary, before a patient’s condi-
tion and nutritional status deteriorates and increases
the risk and complexity of esophageal resection.
Good or excellent results of esophagectomy in 37
achalasia patients were reported by Miller269 in the
‘open’ surgical era, but the complication rate associ-
ated with esophagectomy was high (32.4%) and the
perioperative mortality was 5.4%. A predictive factor
for the need of esophagectomy is the presence of a
massively dilated esophagus (>6 cm).235,270 Loviscek
subdivided his patients with esophagus >6 cm into
those with a tortuous megaesophagus and all the
patients who underwent an esophagectomy (4/504)
were in this last group. Overall, esophagectomy was
required in less than 1% of their entire population
of 504 patients, but it was ultimately required in
17% of those who relapsed after previous surgical
treatment.235
Recommendation: we conditionally recommend
esophagectomy in patients with end-stage achalasia
who have failed other interventions. GRADE Low
Achalasia in children
41. Children with suspected achalasia should follow the
same diagnostic pathway as that of adult patients.
Agree: 96% [D + (0%); D (2%); U (2%); A (66%);
A + (30%)]
There are no systematic studies defining the optimal
diagnostic regime in children. Older children (aged 10
to 17) can and should undergo a work-up similar to
adults; with endoscopy, high-resolution manometry
and a standard or timed barium swallow study.
Obtaining some of these studies in infants and small
children may be difficult due to size mismatch and
compliance. In a cohort of 42 pediatric patients,271 all
had a barium study and endoscopy. 38 patients had
manometry with 4 being too young to tolerate the test.
Unlike adults, biopsies of the GEJ are not mandatory
for the pediatric population due to low risk of cancer
in this population.
Recommendation: we recommend that children with
a provisional diagnosis of achalasia should undergo
the same work-up as in the adult population. Good
practice recommendation.
42. Surgical or endoscopic myotomy (compared to
dilation) is the preferred treatment for pediatric patients
with idiopathic achalasia, especially for those aged 5
years or more.
Agree: 80% [D + (0%); D (6%); U (14%); A (56%);
A + (24%)]
All treatments for achalasia have been shown to be
safe and effective in the pediatric population.272-276
Transthoracic open or thoracoscopic approaches275
have been mostly abandoned due to access trauma,
poor outcomes in the adult experience and inability to
add a partial fundoplication. Instead, an open abdom-
inal or laparoscopic approach is now the only accepted
method accepted in pediatric patients.
While open Heller myotomy is long established
and safe, most centers have converted to less inva-
sive laparoscopic access. Pastor et al., in a large single
center retrospective study documents this institutional
conversion from open to laparoscopic Heller and con-
firms its equal effectiveness and patient benefit.277
Pneumatic balloon dilation remains a popular option
for the pediatric population, though less so than for
adults due, once again, to concerns over the poten-
tial need of multiple reinterventions over the patient’s
lifespan. Another concern is the issue of balloon size
mismatch for the younger children, which limits appli-
cation of balloon dilation to children over the age of 5
years. DiNardo et al. reported an 87% success rate of
PD in pediatric patients >5 years with 6 years follow-
up although patients required an average of three
treatments.274 LHM is often considered the first-line
treatment for pediatric achalasia. Numerous papers
have shown it to be a safe and effective therapy. Sim-
ilar to laparoscopic adult surgery, it is usually accom-
panied by a partial fundoplication, with no conclusion
regarding the superiority of aDor or Toupet fundopli-
cation. Lee et al. presented a retrospective comparison
between surgery or PD.278 They concluded that, in the
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pediatric population, laparoscopic Heller with partial
fundoplication was the best treatment for achalasia.
Today, there are several case series describing
POEM in the pediatric population and showing it is
both feasible and safe273,279,280 but there are only a
few series frompediatric hospitals introducing the new
approach into their treatment algorithm.279 Outcomes
were the same regardless of who performed the proce-
dure. As with PD, there were concerns that the size of
therapeutic endoscopic instrumentation might be too
large for small infants although the youngest patients
in case series are 5 years old and in anecdotal patients
as young as 2 years have been done. Data to date
has shown POEM to be equivalent if not better than
PD or LHM in relief of dysphagia.273,281 While some
investigators have suggested that the reflux prevention
may be less essential in the pediatric population,282,283
it may be that POEM is the ultimate preferred initial
strategy in the pediatric population, but it should be
borne in mind that abnormal reflux after POEM has
the potential to lead to dysplasia or adenocarcinoma
in the esophagus in later life.
Recommendation: we conditionally recommend
myotomy (either through a laparoscopic or flexible
endoscopy approach) as the preferred treatment in
children. GRADE: very low.
43. BTI is not an appropriate first-line therapy in very
young children with achalasia.
Agree: 81.6% [D + (0%); D (6.2%); U (12.2%); A
(36.7%); A + (44.9%)]
BTI likewise has good short-term effect (Ip 2000)
but the short duration of its efficacy (Ip 2000), makes
it unappealing in pediatric patients.271,273,281,283,284
Recommendation: we recommend against BTI as a
first-line therapy in very young children with acha-
lasia, with exceptions for those children who aremed-
ically frail and at high-risk for surgical intervention.
Conditional recommendation. GRADE: very low.
44. The long-term outcome of achalasia treatment
in children should be assessed by symptoms, function,
physical growth, and general development.
Agree: 94% [D + (0%); D (0%); U (6%); A (46%);
A + (48%)]
All series of pediatric achalasia treatments have in
common that the treatment immediately improves the
patients’ QOL and reverses weight loss and failure to
thrive.285-287 Most patients will need repeat treatments
over time, particularly patients having BTI or PD as
an initial treatment. Smits et al., described the lon-
gitudinal experience in the Netherlands where 88%
of PD treated patients had repeat treatment therapy
required in 22% of patients after Heller myotomy.287
A further 26-year single institution series showed
that 83% of PD treated patients had repeated inter-
ventions versus 30% of the myotomy patients.277 In
this series, of the 83% who had repeated interven-
tions, 53% of the initial PD patients had repeated PD
and 30% went on eventually to myotomy. The ini-
tial myotomy patients who required repeated inter-
ventions had either redo myotomy or in one case, an
esophagectomy. Long term follow-up demonstrates
a recurrent need for interventions and a relatively
high incidence of residual or recurrent symptoms. In
the Dutch longitudinal study, with 10-year follow-up,
Eckardt scores >3 was seen in 45% of patients (equal
between PD and HM). GERD symptoms were also
common at long-term follow-up with 76% of initial
Heller patients reporting GERD symptoms and 33%
of post PD patients. These symptoms impact QOL
with scores for general and achalasia specific QOL
being lower in almost all domains compared to age
matched population norms.287
Recommendation: we recommend that the long-term
outcome of achalasia treatment in children should be
closely monitored by symptoms, swallowing function,
physical growth, and general development. Good
practice recommendation.
Diagnosis and management of achalasia secondary to
Chagas disease
45. There are minor differences between the clinical
presentation of idiopathic achalasia and achalasia sec-
ondary to Chagas disease.
Agree: 86.2% [D + (0%); D (2%); U (11.8%); A
(64.7%); A + (21.5%)]
Chagas disease esophagopathy (CDE) is caused
by the infection of the flagellated protozoan Try-
panosoma cruzi, which causes the destruction of the
esophageal autonomic nervous system leading to a
clinical presentation similar to IA.288-291 Although IA
and CDE are very similar, some differences have been
observed between them. The common pathological
pathways in IA and CDE are the loss of neurons of
the myenteric plexus of the esophagus.291,292 How-
ever, in IA there is a selective loss of inhibitory neu-
rons, whereas in CDE both excitatory and inhibitory
neurons are compromised. Several studies have shown
that LES pressure in IA is increased,289,291,293,294 con-
versely, in CDE, LES pressure may be decreased,
normal or increased.288,293,295-298 The two diseases
present a hypersensitivity of the LES to gastrin, and
a predominance of alfa-adrenergic innervation,289,293
but a different response to botulinum toxin injection
that causes the pressure to decrease in IA but only a
partial response in CDE. From a manometric point
of view, most patients with CDE have low amplitude
contractions.
These differences in the two diseases do not signif-
icantly influence the clinical presentation: solid food
dysphagia is the most prevalent symptom (98.8% of
cases); regurgitation, halitosis, pyrosis, and chest pain
were present in more than 60% of CDE patients.299
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In patients with IA, the age of presentation is similar
between both nonadvanced and advanced achalasia,
although symptom duration is significantly longer in
the latter. Given that the two diseases have similar
motor abnormalities of the LES and esophageal body,
the possibilities of treatment are much the same and
the choice of the best option for each patient depends
on the clinical and radiological presentation and on
the experience of the medical service that will perform
the therapy.288,290,292,293 In conclusion, IA and CDE
present someminor differences in esophageal motility,
but manometric and clinical findings are similar.
Recommendation: we conditionally recommend that
diagnostic techniques used for IA should also be used
for CDE, due to the similarities in manometric and
clinical features. GRADE: low.
46. There are no differences in the treatment of
idiopathic achalasia and achalasia specific to Chagas
disease.
Agree: 90% [D + (0%); D (2%); U (8%); A (62%);
A + (28%)]
All treatments for IA may be used in patients
with CDE. In these patients, however, a careful pre-
operative evaluation is mandatory for the associ-
ated involvement of heart, colon, and gallbladder.7,300
While the progression of CDE is slow, late presenta-
tion is common and most of these patients present
with esophageal dilation in which can be massive
in 10 to 40% of them. In one study87 BTI was
effective in 58% of patients at 6 month follow-up.
Good and/or excellent results have been obtained
by PD, though a recurrence rate up to 30% was
reported.7,300-302 Heller myotomy (or some modifi-
cation of it) with anterior or posterior partial fun-
doplication has been adopted.300,303-305 A significant
number of patients with CDE present for the first time
to treatment with end-stage disease, with atonic and
dilated esophagus, and esophagectomy is required as
primary therapy,306-309 although several groups opted
for a first less invasive approach.310 Given the high
number of patients with a massively dilated esoph-
agus and the risk of esophagectomy, alternative pro-
cedures have been suggested including: cardioplasty
plus truncal vagotomy and Roux-en-Y partial gas-
trectomy, Thal-Hatafuku operation, or Merendino
operation.7,307,311-313 Currently, the indications for
esophageal resection are: end-stage disease, both as
the initial treatment or after failure of conservative
operations; concomitant premalignant or malignant
lesions of the esophagus; and esophageal perforation
unsuitable for repair during diagnostic tests, thera-
peutic endoscopy or intraoperatively.7,300,306,308,309
Recommendation: we conditionally recommend that
all treatments for IA may be used for CDE for
symptom relief. GRADE: low.
Appendix 1: search strategies
The search strategy for Medline included the
following key-words: ‘Esophageal achalasia’
‘AND/OR’ ‘Esophageal Manometry’ ‘High Res-
olution Esophageal manometry’; ‘Chicago classifi-
cation’; ‘Barium Swallow’; ‘Timed barium swallow’;
‘Endoscopy’; ‘Pseudoachalasia’; ‘Symptom’ ‘Score
Symptom’ ‘Medical treatment’; ‘Nitrates’; ‘Calcium
blockers’; ‘Sildenafil’; ‘Botulinum Toxin’; ‘Pneu-
matic Dilatation’; Graded Pneumatic Dilatation’;
‘Esophageal Perforation’; ‘Complication’; ‘Per-oral
endoscopic myotomy (POEM)’; ‘Heller Myotomy’;
‘Laparoscopic Heller Myotomy’; ‘Fundoplication’;
‘Recurrence’; ‘Failure’; Megaesophagus’ ‘End-stage
Achalasia’; ‘Esophagectomy’; ‘Esophageal Resec-
tion’; ‘Re-intervention’; ‘Chagas Disease’; ‘Children’;
Genetic Disease.
The search strategies for the other databases were
adapted to the specific vocabulary of each database.
In December 2017, we conducted a further search lim-
ited to the year 2017 (up to December 2017) to update
the references (using the MeSH term: esophageal
achalasia).
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